TuHURA Biosciences (HURA) Cash from Investing Activities (2020 - 2026)
TuHURA Biosciences' (HURA) quarterly Cash from Investing Activities came in at -$48846.0 in Q1 2026, up 95.76% year-on-year from -$24952.4 in Q1 2025, and down 75.39% quarter-over-quarter from -$27850.0 in Q4 2025.
TuHURA Biosciences (HURA) Cash from Investing Activities (2020 - 2026) Analysis & Trends
TuHURA Biosciences' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$48846.0 for Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 95.76% year-over-year to -$48846.0 in Q1 2026; TTM through Mar 2026 was -$233160.0, a 96.38% increase from a year earlier, with the FY2025 full-year figure at -$1.3 million, up 77.94% from the prior year.
- Cash from Investing Activities slipped to -$48846.0 in Q1 2026 per HURA's latest filing, from -$27850.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$20000.0 in Q4 2023 and bottomed at -$5.2 million in Q3 2024.
- The 5-year median for Cash from Investing Activities is -$48846.0 (2026), against an average of -$769063.8.
- Across the five-year window, Cash from Investing Activities sank 5655.24% in 2025 and surged 95.76% in 2026, its largest moves.
- Year by year, Cash from Investing Activities stood at -$232000.0 in 2022, then jumped by 91.38% to -$20000.0 in 2023, then sank by 26044.34% to -$5.2 million in 2024, then jumped by 99.47% to -$27850.0 in 2025, then slumped by 75.39% to -$48846.0 in 2026.
- Per Business Quant, the three latest HURA Cash from Investing Activities figures stand at -$48846.0 (Q1 2026), -$27850.0 (Q4 2025), and -$156464.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | TuHURA Biosciences | 132.62 Mn | 132.62 Mn | - | -48,846.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -48,846.00 |
| Mar 31, 2026 | -48,846.00 |
| Dec 31, 2025 | -27,850.00 |
| Dec 31, 2025 | -27,850.00 |
| Jun 30, 2025 | -156,464.00 |
| Jun 30, 2025 | -156,464.00 |
| Mar 31, 2025 | -1.15 Mn |
| Mar 31, 2025 | -1.15 Mn |
| Sep 30, 2024 | -5.23 Mn |
| Sep 30, 2024 | -5.23 Mn |
| Jun 30, 2024 | -36,498.00 |
| Jun 30, 2024 | -36,498.00 |
| Mar 31, 2024 | -20,000.00 |
| Mar 31, 2024 | -20,000.00 |
| Dec 31, 2023 | -20,000.00 |
| Dec 31, 2023 | -20,000.00 |
| Sep 30, 2022 | -232,000.00 |
| Sep 30, 2022 | -232,000.00 |
| Mar 31, 2021 | -8,000.00 |
| Mar 31, 2021 | -8,000.00 |